New drug duo takes on tough lymphoma
NCT ID NCT07578077
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug, golcadomide, combined with rituximab for people with mantle cell lymphoma that has come back or stopped responding to treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 58 adults will take part, and researchers will monitor side effects and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- golcadomide and rituximab
- What this could lead to
- If successful, this could offer a new treatment option for patients with mantle cell lymphoma that has returned or stopped responding to therapy.
- What could go wrong
- This is an early-phase trial (phase 1/2) with only 58 participants, so results may not apply broadly. Side effects and lack of effectiveness are possible risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Combination therapy aims to outsmart tough lymphoma
- New combo attack on lymphoma shows promise in early trial
- Engineered immune cells target lymphoma after transplant
- New trial aims to bring targeted lymphoma drugs to minority patients
- New drug combo shows promise for Hard-to-Treat lymphoma